TY  - GEN
AU  - Lincoff,A M
AU  - Tcheng,J E
AU  - Califf,R M
AU  - Kereiakes,D J
AU  - Kelly,T A
AU  - Timmis,G C
AU  - Kleiman,N S
AU  - Booth,J E
AU  - Balog,C
AU  - Cabot,C F
AU  - Anderson,K M
AU  - Weisman,H F
AU  - Topol,E J
TI  - Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade
SN  - 1524-4539
PY  - 1999///0430
KW  - Abciximab
KW  - Aged
KW  - Angioplasty, Balloon, Coronary
KW  - statistics & numerical data
KW  - Antibodies, Monoclonal
KW  - therapeutic use
KW  - Biomarkers
KW  - Cause of Death
KW  - Combined Modality Therapy
KW  - Coronary Artery Bypass
KW  - Coronary Disease
KW  - complications
KW  - Creatine Kinase
KW  - blood
KW  - Double-Blind Method
KW  - Drug Therapy, Combination
KW  - Emergencies
KW  - Female
KW  - Follow-Up Studies
KW  - Heparin
KW  - administration & dosage
KW  - Humans
KW  - Immunoglobulin Fab Fragments
KW  - Incidence
KW  - Isoenzymes
KW  - Male
KW  - Middle Aged
KW  - Myocardial Infarction
KW  - mortality
KW  - Myocardial Ischemia
KW  - Platelet Aggregation Inhibitors
KW  - Platelet Glycoprotein GPIIb-IIIa Complex
KW  - antagonists & inhibitors
KW  - Prospective Studies
KW  - Recurrence
KW  - Survival Analysis
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1161/01.cir.99.15.1951
ER  -